Nicholas Lydon

Nicholas B. Lydon ( born February 27, 1957) is an American biochemist and businessman.

Life

Lydon earned in 1978 at the University of Leeds a BA in biochemistry and zoology, and in 1982 a Ph.D. in biochemistry from the University of Dundee. From 1982 to 1985 he worked as a research assistant at Schering -Plough in Lyon and Paris, after which he was until 1997 a research group leader for tyrosine kinase inhibitors at Ciba- Geigy (now Novartis) in Basel. In 1997 he founded the pharmaceutical company Kinetix Pharmaceuticals in Boston, which he headed until 2000. Other biotechnology companies, has been involved in its creation Lydon, are Granite Biopharma, AnaptysBio and Blueprint Medicines. In the latter two it is (as of 2012) still held a senior position.

Work

Lydon is one of the developers of the tyrosine kinase inhibitors imatinib (trade name Gleevec) and dasatinib ( Sprycel trade name ), which represent a new and successful mode of action in the treatment of various tumors, particularly the leukemias.

Thomson Reuters is one of Lydon since 2011 the favorites for the Nobel Prize in Physiology or Medicine ( Thomson Reuters Citation Laureates ).

Awards (selection)

  • 2002 Kettering Prize from the General Motors Cancer Research Foundation
  • 2009 Lasker ~ DeBakey Clinical Medical Research Award
  • 2011 Honorary Doctorate (law ​​) of the University of Dundee
  • 2012 Japan Prize
  • 2013 Fellow of the Royal Society
  • 2013 GlaxoSmithKline Prize of the Royal Society
602261
de